Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188317 · ClinicalTrials.gov registry record · Phase 1
A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01188317 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 44 participants.
The verdict
NCT01188317, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with ibuprofen on renal function, renin-angiotensin system and pharmacokinetics in healthy volunteers. Volunteers will be randomized to receive daily doses of aleglitazar or placebo in combination with ibuprofen. The anticipated time on study drug is 5 weeks.
Interventions
- DRUG placebo
- DRUG ibuprofen
- DRUG aleglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01188317
The ClinicalTrials.gov registry entry for NCT01188317 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01188317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01188317 about?
NCT01188317 is a clinical study titled "A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers". This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with ibuprofen on renal function, renin-angiotensin system and pharmacokinetics in healthy volunteers. Volunteers will be randomized to r...
What is the current status of trial NCT01188317?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2010-06. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01188317?
The interventions under investigation include: placebo (DRUG), ibuprofen (DRUG), aleglitazar (DRUG).
Who is sponsoring clinical trial NCT01188317?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.